Sacituzumab govitecan (Trodelvy®). HTA ID: 22007

Assessment Status NCPE Assessment Process Complete
HTA ID 22007
Drug Sacituzumab govitecan
Brand Trodelvy®
Indication Is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, including at least one of them for advanced disease.  
Assessment Process
Rapid review commissioned 07/02/2022
Rapid review completed 08/03/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of sacituzumab govitecan compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/04/2022
Pre-submission consultation with Applicant 25/04/2022
Full submission received from Applicant 10/08/2022
Preliminary review sent to Applicant 22/12/2022
NCPE assessment re-commenced 01/02/2023
Follow-up to preliminary review sent to Applicant 13/02/2023
NCPE assessment re-commenced 16/02/2023
Factual accuracy sent to Applicant 09/03/2023
NCPE assessment re-commenced 20/03/2023
NCPE assessment completed 24/03/2023
NCPE assessment outcome The NCPE recommends that sacituzumab govitecan be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Technical Summary

Plain English Summary